Developer docs
API playgroundTry for free, no card

Search company profiles

Aktis Oncology

Full company profile

uuid00007hx

Namestring
Aktis Oncology
Legal namestring
Aktis Oncology, Inc.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Aktis Oncology is a clinical-stage biotechnology company founded in 2020 and headquartered in Boston, Massachusetts, with research operations in Research Triangle Park, North Carolina. The company is developing a proprietary class of targeted radiopharmaceuticals designed to address solid tumor types that have historically been beyond the reach of approved radiopharmaceutical therapies. Its integrated offering centers on a proprietary miniprotein radioconjugate platform that engineers custom tumor-targeting ligands paired with the alpha-emitting radioisotope actinium-225, exploiting the high cell-killing potency of alpha particles while sparing healthy tissue through rapid systemic clearance. Integrated theranostic imaging agents (e.g., Ga-68 labeled counterparts) enable visualization of tumor uptake to guide patient selection.

The company's clinical pipeline includes AKY-1189, a Nectin-4-targeted radioconjugate that received FDA Fast Track Designation for locally advanced or metastatic urothelial cancer and is currently in a multi-site U.S. Phase 1b study (NCT07020117) across urothelial, breast, NSCLC, colorectal, cervical, and head and neck cancers; AKY-2519, a B7-H3-targeted radioconjugate in a U.S. Phase 1b trial (NCT07581184) for metastatic castration-resistant prostate cancer with first-in-human data presented at ASCO 2026; undisclosed radioconjugate programs under a 2024 discovery collaboration with Eli Lilly; and additional discovery-stage programs. The company completed a $365.4 million IPO on Nasdaq in January 2026 under ticker AKTS, with pro forma cash of approximately $562.1 million expected to fund operations into 2029.

Aktis's business model is currently collaboration-driven rather than product-driven. Revenue is generated from the Eli Lilly strategic research partnership (which includes a $60 million upfront payment and potential milestone payments up to $1.1 billion), recording $4.6 million in revenue for the nine months ended September 30, 2025, against a $63.7 million net loss for FY2025. The company is pre-commercial with no approved products; future revenue is expected to derive from direct sales of approved radiopharmaceutical therapies in the U.S. and potential partner-driven commercialization in other geographies, supported by an in-house manufacturing and just-in-time supply chain capability being built out for short-shelf-life radiopharmaceuticals. Customer segments are dual: oncology patients with Nectin-4 or B7-H3 expressing solid tumors (urothelial, breast, NSCLC, colorectal, cervical, head and neck, mCRPC, lung) and large pharmaceutical companies seeking differentiated radiopharmaceutical platforms.

Short descriptiontext

Aktis Oncology is a clinical-stage biotechnology company developing proprietary miniprotein radioconjugate therapies that deliver actinium-225 alpha radiation to solid tumors expressing Nectin-4 or B7-H3, targeting patient populations beyond the reach of approved radiopharmaceuticals like Lutathera and Pluvicto.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted radiopharmaceuticals, alpha-emitting therapeutics, miniprotein radioconjugates, cancer drug development, solid tumor therapeutics
Industry1 code
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Radiopharmaceuticals for Oncology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration & Licensing Revenue (Eli Lilly Partnership)
TypeLicensing Royalties
Description

Revenue generated from the strategic research collaboration with Eli Lilly, including an upfront payment of $60 million and potential milestone payments up to $1.1 billion in aggregate for novel radioconjugates developed using Aktis's miniprotein platform. Recorded $4.6 million in revenue for the nine months ended September 30, 2025.

investing.com
2Future Direct Product Sales (Planned)
TypeOne Time License
Description

Currently pre-commercial clinical-stage company with no approved products; revenue model upon commercialization expected to rely on direct sales of approved radiopharmaceutical therapies for solid tumors in the U.S. and potentially partner-driven commercialization in other geographies.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aktis Oncology is a clinical-stage biotechnology company developing a new class of targeted alpha-emitting radiopharmaceuticals for solid tumors. Its proprietary miniprotein radioconjugate platform engineers tumor-targeting ligands that deliver actinium-225 (an alpha-emitter) payloads directly to cancer cells with deep tumor penetration, long residence times, and rapid systemic clearance. Lead clinical-stage candidates include AKY-1189 (Nectin-4, FDA Fast Track Designation for urothelial cancer) and AKY-2519 (B7-H3, Phase 1b for mCRPC), supported by a discovery collaboration with Eli Lilly and additional undisclosed programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Eli Lilly committed up to $1.1 billion in potential milestones plus $60M upfront payment under strategic research partnership
+4 more records
Product overview1 text field

Aktis Oncology offers a single integrated offering centered on its proprietary miniprotein radioconjugate platform, which powers a pipeline of clinical-stage and discovery-stage targeted alpha-emitting radiopharmaceuticals for solid tumors. The platform generates product candidates — most notably the clinical-stage assets AKY-1189 (targeting Nectin-4 expressing tumors, with FDA Fast Track designation in urothelial cancer) and AKY-2519 (targeting B7-H3 expressing tumors such as mCRPC and lung cancer) — along with partnered programs under the existing discovery collaboration with Eli Lilly and additional multiple undisclosed discovery programs. Together, the platform, the named clinical assets, and the partnered/discovery programs constitute Aktis's portfolio for delivering actinium-225 payloads to tumor sites with high precision and limited normal tissue exposure.

Product and service4 records
1Miniprotein Radioconjugate Platform
CategoryCore Technology Platform
Description

Aktis Oncology's proprietary discovery and development platform that generates custom-engineered targeted radiopharmaceuticals to deliver powerful alpha-emitting radioisotopes (actinium-225) directly to tumors. The platform enables precision targeting with deep tumor penetration, long residence times, and rapid clearance from normal tissues, and supports a theranostic approach to visualize and verify tumor target engagement.

2AKY-1189
CategoryClinical-stage Product Candidate
Description

A miniprotein radioconjugate designed to deliver actinium-225 to Nectin-4 expressing solid tumors. Granted FDA Fast Track Designation for locally advanced or metastatic urothelial cancer (mUC) in patients who have progressed on or after prior systemic therapies. Currently in a multi-site U.S. Phase 1b study (NCT07020117, NECTINIUM-2) for mUC, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer.

3AKY-2519
CategoryClinical-stage Product Candidate
Description

A miniprotein radioconjugate designed to deliver actinium-225 to B7-H3 expressing tumors. Currently in a multi-site U.S. Phase 1b trial (NCT07581184) for metastatic castration-resistant prostate cancer (mCRPC). A second Phase 1b basket trial in lung, colorectal, and other B7-H3 expressing solid tumors is planned for H2 2026. First-in-human imaging and dosimetry data presented at ASCO 2026.

4Aktis-Lilly Discovery Collaboration Programs
CategoryPartnered Discovery Program
Description

Undisclosed targets under an existing discovery collaboration with Eli Lilly to develop novel radioconjugates using Aktis's miniprotein platform, for which Aktis received a $60 million upfront payment as part of a broader partnership valued at up to $1.1 billion in potential milestones.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Eli Lilly partnered with Aktis Oncology to develop novel tumor-targeting radiopharmaceuticals using Aktis's miniprotein platform. The deal included a $60 million upfront payment to Aktis and up to $1.1 billion in potential milestone payments. Lilly also served as anchor investor in Aktis's January 2026 IPO, purchasing approximately $100 million of shares at the IPO price, validating the platform. The discovery collaboration targets undisclosed radioconjugate programs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers4 records
TypeBroad incumbent
TypeBroad incumbent
Description

Lantheus is a leading radiopharmaceutical company with commercial products (e.g., PYLARIFY, Definity) and a broad pipeline in oncology and diagnostics. As a broad incumbent in the targeted radiopharma space, it competes with Aktis for share-of-mind in solid-tumor imaging and therapy, though its portfolio is more diversified.

TypeDirect peer
Description

Telix is a commercial-stage radiopharma company marketing Illuccix (PSMA-PET imaging) and developing therapeutic radiopharmaceuticals across prostate cancer and other solid tumors. It is a direct peer to Aktis in the targeted radiopharmaceutical oncology space, with overlapping targets and clinical ambitions.

TypeBroad incumbent
Description

Novartis owns Advanced Accelerator Applications (AAA) and the Pluvicto/Lutathera franchises, the dominant approved radiopharmaceutical therapies. As a broad incumbent, it competes head-on with Aktis's solid-tumor ambitions and already has a leading radioligand commercial infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aktis Oncology

Targeted Radiopharmaceuticals for Oncologyaktisoncology.com

Aktis Oncology is a clinical-stage biotechnology company developing proprietary miniprotein radioconjugate therapies that deliver actinium-225 alpha radiation to solid tumors expressing Nectin-4 or B7-H3, targeting patient populations beyond the reach of approved radiopharmaceuticals like Lutathera and Pluvicto.

What Aktis Oncology does

Aktis Oncology is a clinical-stage biotechnology company founded in 2020 and headquartered in Boston, Massachusetts, with research operations in Research Triangle Park, North Carolina. The company is developing a proprietary class of targeted radiopharmaceuticals designed to address solid tumor types that have historically been beyond the reach of approved radiopharmaceutical therapies. Its integrated offering centers on a proprietary miniprotein radioconjugate platform that engineers custom tumor-targeting ligands paired with the alpha-emitting radioisotope actinium-225, exploiting the high cell-killing potency of alpha particles while sparing healthy tissue through rapid systemic clearance. Integrated theranostic imaging agents (e.g., Ga-68 labeled counterparts) enable visualization of tumor uptake to guide patient selection.

The company's clinical pipeline includes AKY-1189, a Nectin-4-targeted radioconjugate that received FDA Fast Track Designation for locally advanced or metastatic urothelial cancer and is currently in a multi-site U.S. Phase 1b study (NCT07020117) across urothelial, breast, NSCLC, colorectal, cervical, and head and neck cancers; AKY-2519, a B7-H3-targeted radioconjugate in a U.S. Phase 1b trial (NCT07581184) for metastatic castration-resistant prostate cancer with first-in-human data presented at ASCO 2026; undisclosed radioconjugate programs under a 2024 discovery collaboration with Eli Lilly; and additional discovery-stage programs. The company completed a $365.4 million IPO on Nasdaq in January 2026 under ticker AKTS, with pro forma cash of approximately $562.1 million expected to fund operations into 2029.

Aktis's business model is currently collaboration-driven rather than product-driven. Revenue is generated from the Eli Lilly strategic research partnership (which includes a $60 million upfront payment and potential milestone payments up to $1.1 billion), recording $4.6 million in revenue for the nine months ended September 30, 2025, against a $63.7 million net loss for FY2025. The company is pre-commercial with no approved products; future revenue is expected to derive from direct sales of approved radiopharmaceutical therapies in the U.S. and potential partner-driven commercialization in other geographies, supported by an in-house manufacturing and just-in-time supply chain capability being built out for short-shelf-life radiopharmaceuticals. Customer segments are dual: oncology patients with Nectin-4 or B7-H3 expressing solid tumors (urothelial, breast, NSCLC, colorectal, cervical, head and neck, mCRPC, lung) and large pharmaceutical companies seeking differentiated radiopharmaceutical platforms.

Aktis Oncology firmographics

Firmographics
Name
Aktis Oncology
Legal name
Aktis Oncology, Inc.
Website
https://aktisoncology.com
Company type
Public
Founded year
2020
Operating status
Ipo
Headcount range
101–250 employees
Short description
Aktis Oncology is a clinical-stage biotechnology company developing proprietary miniprotein radioconjugate therapies that deliver actinium-225 alpha radiation to solid tumors expressing Nectin-4 or B7-H3, targeting patient populations beyond the reach of approved radiopharmaceuticals like Lutathera and Pluvicto.
Ownership category
akta.pro rank

Aktis Oncology industry classification

Industry
Product category
Targeted Radiopharmaceuticals for Oncology
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted radiopharmaceuticals
  • Alpha-emitting therapeutics
  • Miniprotein radioconjugates
  • Cancer drug development
  • Solid tumor therapeutics

Where Aktis Oncology is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aktis Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Collaboration & Licensing Revenue (Eli Lilly Partnership): Revenue generated from the strategic research collaboration with Eli Lilly, including an upfront payment of $60 million and potential milestone payments up to $1.1 billion in aggregate for novel radioconjugates developed using Aktis's miniprotein platform. Recorded $4.6 million in revenue for the nine months ended September 30, 2025.
  2. Future Direct Product Sales (Planned): Currently pre-commercial clinical-stage company with no approved products; revenue model upon commercialization expected to rely on direct sales of approved radiopharmaceutical therapies for solid tumors in the U.S. and potentially partner-driven commercialization in other geographies.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Aktis Oncology product offering

Product offering

Core offering

Aktis Oncology is a clinical-stage biotechnology company developing a new class of targeted alpha-emitting radiopharmaceuticals for solid tumors. Its proprietary miniprotein radioconjugate platform engineers tumor-targeting ligands that deliver actinium-225 (an alpha-emitter) payloads directly to cancer cells with deep tumor penetration, long residence times, and rapid systemic clearance. Lead clinical-stage candidates include AKY-1189 (Nectin-4, FDA Fast Track Designation for urothelial cancer) and AKY-2519 (B7-H3, Phase 1b for mCRPC), supported by a discovery collaboration with Eli Lilly and additional undisclosed programs.

Product overview

Aktis Oncology offers a single integrated offering centered on its proprietary miniprotein radioconjugate platform, which powers a pipeline of clinical-stage and discovery-stage targeted alpha-emitting radiopharmaceuticals for solid tumors. The platform generates product candidates — most notably the clinical-stage assets AKY-1189 (targeting Nectin-4 expressing tumors, with FDA Fast Track designation in urothelial cancer) and AKY-2519 (targeting B7-H3 expressing tumors such as mCRPC and lung cancer) — along with partnered programs under the existing discovery collaboration with Eli Lilly and additional multiple undisclosed discovery programs. Together, the platform, the named clinical assets, and the partnered/discovery programs constitute Aktis's portfolio for delivering actinium-225 payloads to tumor sites with high precision and limited normal tissue exposure.

Differentiator

Problem solved

Functional benefit

Products and services

  • Miniprotein Radioconjugate Platform Aktis Oncology's proprietary discovery and development platform that generates custom-engineered targeted radiopharmaceuticals to deliver powerful alpha-emitting radioisotopes (actinium-225) directly to tumors. The platform enables precision targeting with deep tumor penetration, long residence times, and rapid clearance from normal tissues, and supports a theranostic approach to visualize and verify tumor target engagement.
  • AKY-1189 A miniprotein radioconjugate designed to deliver actinium-225 to Nectin-4 expressing solid tumors. Granted FDA Fast Track Designation for locally advanced or metastatic urothelial cancer (mUC) in patients who have progressed on or after prior systemic therapies. Currently in a multi-site U.S. Phase 1b study (NCT07020117, NECTINIUM-2) for mUC, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer.
  • AKY-2519 A miniprotein radioconjugate designed to deliver actinium-225 to B7-H3 expressing tumors. Currently in a multi-site U.S. Phase 1b trial (NCT07581184) for metastatic castration-resistant prostate cancer (mCRPC). A second Phase 1b basket trial in lung, colorectal, and other B7-H3 expressing solid tumors is planned for H2 2026. First-in-human imaging and dosimetry data presented at ASCO 2026.
  • Aktis-Lilly Discovery Collaboration Programs Undisclosed targets under an existing discovery collaboration with Eli Lilly to develop novel radioconjugates using Aktis's miniprotein platform, for which Aktis received a $60 million upfront payment as part of a broader partnership valued at up to $1.1 billion in potential milestones.

Quantifiable outcome

  • Eli Lilly committed up to $1.1 billion in potential milestones plus $60M upfront payment under strategic research partnership
  • +4 more outcomes

Companies that use Aktis Oncology

Customer profile

Segments3 records

Ideal customer profiles2 records

Aktis Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Aktis Oncology partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 1 January 2024Eli Lilly partnered with Aktis Oncology to develop novel tumor-targeting radiopharmaceuticals using Aktis's miniprotein platform. The deal included a $60 million upfront payment to Aktis and up to $1.1 billion in potential milestone payments. Lilly also served as anchor investor in Aktis's January 2026 IPO, purchasing approximately $100 million of shares at the IPO price, validating the platform. The discovery collaboration targets undisclosed radioconjugate programs.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Aktis Oncology competitors and assessment

Company assessment

Broad incumbents

  • Bayer (Xofigo / Algeta legacy):
  • Lantheus Holdings: Lantheus is a leading radiopharmaceutical company with commercial products (e.g., PYLARIFY, Definity) and a broad pipeline in oncology and diagnostics. As a broad incumbent in the targeted radiopharma space, it competes with Aktis for share-of-mind in solid-tumor imaging and therapy, though its portfolio is more diversified.
  • Novartis (AAA / Pluvicto / Lutathera): Novartis owns Advanced Accelerator Applications (AAA) and the Pluvicto/Lutathera franchises, the dominant approved radiopharmaceutical therapies. As a broad incumbent, it competes head-on with Aktis's solid-tumor ambitions and already has a leading radioligand commercial infrastructure.

Direct peers

  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharma company marketing Illuccix (PSMA-PET imaging) and developing therapeutic radiopharmaceuticals across prostate cancer and other solid tumors. It is a direct peer to Aktis in the targeted radiopharmaceutical oncology space, with overlapping targets and clinical ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Aktis Oncology social profiles

Digital presence

Aktis Oncology compliance and trust

Trust signal

Compliance1 record

Aktis Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aktis Oncology leadership team

Management profile

Number of profiles

Profiles20 records

Aktis Oncology subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aktis Oncology funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aktis Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aktis Oncology

What does Aktis Oncology do?

Aktis Oncology is a clinical-stage biotechnology company developing a new class of targeted alpha-emitting radiopharmaceuticals for solid tumors. Its proprietary miniprotein radioconjugate platform engineers tumor-targeting ligands that deliver actinium-225 (an alpha-emitter) payloads directly to cancer cells with deep tumor penetration, long residence times, and rapid systemic clearance. Lead clinical-stage candidates include AKY-1189 (Nectin-4, FDA Fast Track Designation for urothelial cancer) and AKY-2519 (B7-H3, Phase 1b for mCRPC), supported by a discovery collaboration with Eli Lilly and additional undisclosed programs.

Is Aktis Oncology a public or private company?

Aktis Oncology is a public company. It is classified as public and is currently ipo.

When was Aktis Oncology founded?

Aktis Oncology was founded in 2020. It employs 101 to 250 people.

Where is Aktis Oncology based?

Aktis Oncology is headquartered in Boston, United States, in the North America region.

How does Aktis Oncology make money?

Two revenue lines are on record. Collaboration & Licensing Revenue (Eli Lilly Partnership) is the primary driver. The others are future Direct Product Sales (Planned).

Who are Aktis Oncology's main competitors?

Broad incumbents on record are Bayer (Xofigo / Algeta legacy), Lantheus Holdings and Novartis (AAA / Pluvicto / Lutathera). Telix Pharmaceuticals is listed as a direct peer.

Does Aktis Oncology have an API?

No public API is recorded for Aktis Oncology.

What industry is Aktis Oncology in?

Aktis Oncology's product category is Targeted Radiopharmaceuticals for Oncology. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAktis Oncology Reports Q3 2026 Results, $492.9M Cash PositionAktis Oncology reported Q3 2026 collaboration revenue of $3.9 million and a net loss of $29.9 million. Cash, cash equivalents, and marketable securities totaled $492.9 million as of September 30, 2026, which the company expects to fund its operating plan into 2029. The company initiated its third Phase 1b trial and expects preliminary clinical data from two programs in 2027.American Banking and Market NewsAktis Oncology (AKTS) Expected to Release Earnings on ThursdayAktis Oncology is expected to release Q3 2026 earnings on November 12th, with analysts forecasting a loss of $0.47 per share and revenue of $4.02 million. The company's stock opened at $17.45, and analysts have a consensus rating of Moderate Buy with a target price of $35.62.Simply Wall StCompanies Like Aktis Oncology (NASDAQ:AKTS) Are In A Position To Invest In GrowthAktis Oncology has a cash runway of about 6.1 years with $517m in cash and $85m annual cash burn. Its cash burn rose 102% year-over-year, but revenue grew 81% annually. The company could raise cash easily, as burn is 9.6% of market cap.American Banking and Market NewsAktis Oncology (NASDAQ:AKTS) Stock Has Consensus Target Price of $35.62 According to BrokeragesAktis Oncology shares opened at $15.73, down 6.1%, with a consensus target of $35.62 from eleven analysts. The company reported a Q2 loss of $0.44 per share, missing the $0.43 consensus, while revenue of $3.38 million beat the $2.70 million estimate. Analysts expect a -1.84 EPS for the current year.Markets DailyAktis Oncology (AKTS) – What Are Investment Firms Thinking About This Stock?Aktis Oncology shares have a consensus 'Moderate Buy' rating from 11 analysts, with an average 12-month price target of $35.62. The company reported a quarterly loss of $0.44 per share, missing estimates, and revenue of $3.38 million. Institutional investors hold 28.84% of the stock.MarketBeatAktis Oncology (AKTS) - What Are Researchers Saying About This Stock?Aktis Oncology shares have a consensus 'Moderate Buy' rating from 11 analysts, with an average 12-month price target of $35.62. Institutional investors own 28.84% of the stock, and the company reported a loss of $0.44 per share for the quarter, missing estimates.Markets DailyAktis Oncology $AKTS Stock Purchased by Mirador Capital Partners LPMirador Capital Partners LP increased its stake in Aktis Oncology by 232.9% in Q3, holding 133,558 shares valued at $2.6 million. Analysts have set a consensus price target of $35.62, with an average rating of Moderate Buy. The company reported a loss of $0.44 per share for the quarter.MarketBeat93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LPMirador Capital Partners LP raised its stake in Aktis Oncology by 232.9% in Q3, acquiring 93,434 additional shares. The firm now holds 133,558 shares, about 0.25% of the company. Analysts have an average "Moderate Buy" rating with a $35.62 target price.American Banking and Market NewsOncocyte (NASDAQ:IMDX) & Aktis Oncology (NASDAQ:AKTS) Head-To-Head SurveyA head-to-head survey compares Aktis Oncology and Oncocyte, finding Oncocyte has higher upside potential. Oncocyte's consensus price target is $10.50 (205.23% upside) versus Aktis's $35.62 (92.36% upside). Oncocyte also has higher institutional ownership at 55.3%.Defense WorldAktis Oncology’s (AKTS) Outperform Rating Reaffirmed at WedbushWedbush reaffirmed an outperform rating on Aktis Oncology with a $35 target. The stock opened at $18.52, and the company reported a loss of $0.44 per share for the quarter, missing estimates. Analysts have an average rating of Moderate Buy with a $35.62 target.